Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus

This study has been terminated.
Information provided by (Responsible Party):
Nang Kuang Pharmaceutical Co., Ltd. Identifier:
First received: December 9, 2013
Last updated: March 28, 2017
Last verified: March 2017
Investigator will assign 53 patients who had been histologically proven localized squamous cell carcinoma of esophagus to receive the induction chemotherapy regimen of ND-420 50 mg/m2 on day 1, cisplatin 70 mg/m2 on day1, plus fluorouracil 700 mg/m2 daily, day1 to day4, every 3 weeks for 2 cycles and then followed by surgical resection. The successful rate of complete treatment per protocol and complete resection will be the primary variant to evaluate in our study.

Condition Intervention Phase
Localized Squamous Cell Carcinoma of the Esophagus
Drug: ND-420
Procedure: Surgery
Drug: Cisplatin
Drug: fluorouracil
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus

Resource links provided by NLM:

Further study details as provided by Nang Kuang Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • the R0 resection rate of participants [ Time Frame: up to three months ]

Secondary Outcome Measures:
  • the response rate (RECIST) of participants [ Time Frame: up to three months ]
  • Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: up to one year ]
  • the population pharmacokinetic parameters (Cmax, AUC... )of ND-420 in the participants [ Time Frame: 0, 30min, 1hr of ND-420 infusion. selected randomly form one of 3hr, 7hr, 11hr and 23hr after the end of ND-420 infusion. ]
  • the correlation between clinical outcomes and the potential predictive genomic biomarkers(B-tubulin mutation, p53-Arg 72Pro, Bcl2-C938A, MDR1-C3435T polymorphism, TNFRSF1B-1466, GSTP1-l105V, CYP1B1, TS-5'UTR) for tumor response [ Time Frame: up to one year ]
  • 1-year survival rate of participants [ Time Frame: up to one year ]
  • pathologic complete response rate of participants [ Time Frame: up to one year ]
  • 1-year progression free survival rate of participants [ Time Frame: up to one year ]
  • 1-year overall survival rate of participants [ Time Frame: up to one year ]

Enrollment: 48
Study Start Date: August 2013
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Induction Chemotherapy DCF followed by Surgery
All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
Drug: ND-420
ND-420 50 mg/m2 on day1
Other Name: ND-420(Nangkuang)
Procedure: Surgery
After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
Drug: Cisplatin
cisplatin 70 mg/m2 on day1
Drug: fluorouracil
fluorouracil 700 mg/m2 daily, day1 to day4
Other Name: 5-FU


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have been histologically proven esophageal carcinoma (squamous cell carcinoma).
  • The tumor had to be locally advanced (stage T2-3/N0, T1-3/N+, if technically resectable with curative intent).
  • Patients must be 20 years of age.
  • Patients must have an ECOG performance status score 2.
  • Patients must have a life expectancy of at least 12 weeks.
  • Patients must be accessible for treatment and follow-up at least for one year.
  • Patients must sign the informed consent form.
  • Patient must have:Hemoglobin level 9 g/dl; Neutrophil count 1,500/mm3; Platelets count 100,000/mm3; Serum bilirubin level 1.0 ULN; Serum transaminase (GOT, GPT) levels 2.0 ULN; Serum Alkaline phosphatase levels 2.0 ULN; Serum creatinine level 1.5 mg/dl or Creatinine clearance rate(CrCl)60 ml/min for the institution (calculated by the Cockcroft- Gault equation).

Exclusion Criteria:

  • Patient who are receiving or had received concurrent radiotherapy, chemotherapy or other anticancer treatment for esophageal carcinoma.
  • Patients with known history of severe hypersensitivity reactions to any medicine or to drugs formulated with polysorbate 80.
  • Major surgery within two weeks prior to entering the study, excluding port-A insertion or feeding jejunostomy surgery.
  • Patients with CNS metastasis, including clinical suspicion.
  • Patients with clinically detectable peripheral neuropathy 2 on the CTC criteria.
  • Mental statuses of patients are not fit for clinical trial.
  • Fertile men and women unless using a reliable and appropriate contraceptive method.
  • Patients with pregnancy or lactating, women considering pregnancy, possible pregnancy that without using effective contraception.
  • Patients who have serious concomitant illness that might be aggravated by chemotherapy, as below included:Active cardiac disease (e.g. congestive heart failure, angina, arrhythmia, acute myocardial disease or other types of heart disease requiring treatment) within 6 months period preceding entry into the study; Uncontrolled infection (e.g. active infection that uncontrolled for 2 weeks under antibiotic therapy); Retention of body fluid (e.g. pleural effusion, ascites, pericardial effusion, and edema needing treatment); History of other than esophageal cancer, except curatively treated non-melanoma skin cancer or in situ carcinoma of the esophagus; and other conditions which will be judged by physician's discretion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02017600

Taipei Veterans General Hospital
Taipei, Taiwan, 112
Sponsors and Collaborators
Nang Kuang Pharmaceutical Co., Ltd.
Principal Investigator: Ming-Huang Chen, M.D. Taipei Veterans General Hospital, Taiwan
  More Information

Responsible Party: Nang Kuang Pharmaceutical Co., Ltd. Identifier: NCT02017600     History of Changes
Other Study ID Numbers: NKCND420/201112
Study First Received: December 9, 2013
Last Updated: March 28, 2017

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017